Voloridge Investment Management
RLMD icon

Voloridge Investment Management’s Relmada Therapeutics RLMD Stock Holding History

Voloridge Investment Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-91,264
Closed -$274K – 1426
2023
Q3 		$274K Sell
91,264
-60,971
-40% -$181K ﹤0.01% 1289
2023
Q2 		$374K Sell
152,235
-105,688
-41% -$292K ﹤0.01% 1269
2023
Q1 		$583K Sell
257,923
-75,174
-23% -$259K ﹤0.01% 1202
2022
Q4 		$1.16M Buy
333,097
+228,826
+219% +$2.01M 0.01% 1103
2022
Q3 		$3.86M Buy
+104,271
New +$2.89M 0.02% 746

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Voloridge Investment Management's RLMD Position: Q4 2023 in Review

Voloridge Investment Management sold out of Relmada Therapeutics (RLMD) in Q4 2023, closing a stake of 91,264 shares — an estimated $274K sold.

Voloridge Investment Management first reported a position in RLMD in Q3 2022 and held it in 5 quarters. The position peaked at $3.86M in Q3 2022. 83 funds tracked by Wall St. Rank hold RLMD as of Q4 2023.

  • Voloridge Investment Management reported no remaining Relmada Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Voloridge Investment Management sold 91,264 Relmada Therapeutics shares in Q4 2023, an estimated $274K.
  • Voloridge Investment Management first reported a position in Relmada Therapeutics in Q3 2022 and held it in 5 quarters.
  • Voloridge Investment Management's Relmada Therapeutics position peaked at $3.86M in Q3 2022.
  • 83 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2023.

Based on Voloridge Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.